BioCentury
ARTICLE | Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

December 21, 2018 7:47 PM UTC

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages.

Annexon is developing inhibitors of the classical complement pathway to treat neurodegenerative, autoimmune and ophthalmic diseases. ANX005, a humanized mAb that inhibits complement component 1 q subcomponent (C1q), is in Phase Ib testing for autoimmune and neurodegenerative diseases. ANX007, a Fab antibody fragment targeting C1q, is in Phase Ib testing for ophthalmic diseases, including glaucoma. The company expects Phase Ib data from both programs next year and hopes to start Phase II testing in 2020...

BCIQ Company Profiles

Annexon Inc.